Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Unattributed - II | Alive

Total Raised


Last Raised

$1.31M | 9 yrs ago

About AkesoGenX

AkesoGenX bring to market significant new nano-diagnostic and nano-therapeutic medical products. The primary goal is to move the Kanzius RF field treatment forward to treat patients with highly lethal and resistant forms of cancer.

AkesoGenX Headquarters Location

10955 Westmoor Suite 400

Broomfield, Colorado, 80021,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing AkesoGenX

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AkesoGenX is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

  • Where is AkesoGenX's headquarters?

    AkesoGenX's headquarters is located at 10955 Westmoor, Broomfield.

  • What is AkesoGenX's latest funding round?

    AkesoGenX's latest funding round is Unattributed - II.

  • How much did AkesoGenX raise?

    AkesoGenX raised a total of $1.51M.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.